Načítá se...
The Immune Response to the fVIII Gene Therapy in Preclinical Models
Neutralizing antibodies to factor VIII (fVIII), referred to as “inhibitors,” remain the most challenging complication post-fVIII replacement therapy. Preclinical development of novel fVIII products involves studies incorporating hemophilia A (HA) and wild-type animal models. Though immunogenicity is...
Uloženo v:
| Vydáno v: | Front Immunol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7174743/ https://ncbi.nlm.nih.gov/pubmed/32351497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00494 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|